TICKERNERD
Menu
AMIXAMIXHealthcare · Medical Devices

AMIX Stock Forecast: Autonomix Medical, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.81

The 2 Wall Street analysts covering Autonomix Medical, Inc. hold a median 12-month price target of $41 — +2154.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.5M
Ticker Nerd rank
27/ 100
Median analyst target
$41
Analysts covering
2
Revenue$0.0
Operating income−$2.8M
Net income−$2.7M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

AMIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Autonomix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Revisions
87
Accruals
57
Momentum
28
Growth
27
Issuance
26
Quality
5
Volatility
5
Value
5

Size (96): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AMIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMIX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $6Median $41High $76

The green dot is the last close — the median target sits +2154.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Feb 2026Maxim GroupMaintainsBuy$5.00 → $2.00
29 Apr 2025Maxim GroupInitiatesBuy—
3 Sept 2024Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AMIX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

AMIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Autonomix Medical, Inc. (AMIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 86% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−316.0%

Higher than 5% of US stocks

Return on assets
−157.8%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Autonomix Medical, Inc. (AMIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Autonomix Medical, Inc. has a market value of $3.5M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.2M.

  • Shares outstanding: 543,000.

  • Trailing P/E: −0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Autonomix Medical, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

AMIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AMIXAutonomix Medical, Inc.$3.5M27
XAIRBeyond Air, Inc.$3.7M42
VVOSVivos Therapeutics, Inc.$3.8M37
CODXCo-Diagnostics, Inc.$3.2M39
NUWENuwellis, Inc.$3.1M15
ICCMIceCure Medical Ltd.$3.0M42
AIDX20/20 Biolabs, Inc.$2.8M3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Autonomix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMIX news & analysis

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

GlobeNewsWire · 2 Oct 2026positive

Autonomix Medical announced it has strengthened its patent protection for its platform technology, expanding coverage for catheter-based technologies that enable transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall.

Why it matters — Expanded patent protection helps safeguard Autonomix's core platform technology and its intellectual property position for its catheter-based precision access and treatment delivery systems.

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

GlobeNewsWire · 30 Sept 2026positive

Autonomix reported positive FDA pre-submission feedback supporting a Class II 510(k) strategy for its standalone sensing platform, leveraging substantial equivalence to a previously cleared device. This positions the company for potential initial U.S. clearance in approximately 15 months.

Why it matters — FDA feedback validating a 510(k) pathway could support a more streamlined route toward initial U.S. clearance of Autonomix's sensing platform, a key commercial milestone for the company.

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

GlobeNewsWire · 24 Sept 2026positive

Autonomix Medical announced that it has obtained a European patent that strengthens protection for its proprietary autonomic nervous system assessment technologies, further expanding the company's international intellectual property portfolio and supporting its precision neuromodulation platform.

Why it matters — AMIX watchers would care because this expands the company's global intellectual property footprint and bolsters protection around the technology underpinning its precision neuromodulation platform.

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

GlobeNewsWire · 16 Sept 2026positive

Autonomix Medical, Inc. announced the appointment of Sandra Cohen Kalter, former Chief Regulatory Counsel at Medtronic, to its Board of Directors. Kalter brings more than four decades of MedTech leadership, FDA regulatory, and strategic transaction experience, including work supporting renal denervation and other category-defining technologies.

Why it matters — AMIX watchers would care because adding a veteran regulatory and MedTech leader with deep FDA experience could strengthen the company's regulatory and strategic capabilities for its product development efforts.

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

GlobeNewsWire · 1 Sept 2026positive

Autonomix Medical announced that two scientific abstracts have been accepted for poster presentation at the CIRSE 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The abstracts highlight the potential of Autonomix's transvascular technology in pain management and nervous system mapping.

Why it matters — The acceptance of the abstracts for a major European radiological congress provides third-party validation and increased visibility for Autonomix's transvascular technology across pain management and nervous system mapping.

FAQ

Frequently asked questions about AMIX stock

What is the AMIX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Autonomix Medical, Inc. have a median 12-month price target of $41, with estimates ranging from $6 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMIX stock a buy right now?

Of the 2 analysts covering Autonomix Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Autonomix Medical, Inc. 27 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMIX?

As at 31 Oct 2026, Autonomix Medical, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will AMIX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2154.1% from the last close, and Ticker Nerd's factor model ranks Autonomix Medical, Inc. 27 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMIX stock forecast for 2030?

No analyst covering Autonomix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $76 over the next 12 months.

What does Autonomix Medical, Inc. do?

Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system.

What is the latest news on AMIX?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation". Autonomix Medical announced it has strengthened its patent protection for its platform technology, expanding coverage for catheter-based technologies that enable transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall.

Company

About Autonomix Medical, Inc.

Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its current platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity from within the vascular system. The company is developing this technology for applications in pancreatic cancer and pancreatitis, while also addressing areas such as chronic pain management, hypertension, cardiovascular conditions, and other nerve-related disorders. Autonomix Medical Inc. operates as a single-segment business dedicated to improving how neural conditions are diagnosed and treated through minimally invasive, signal-detection-based tools. Headquartered in The Woodlands, Texas, Autonomix Medical Inc. serves the medical technology market with a specialized focus on nerve-targeted interventions and disease management.

CEO Mr. Bradley Hauser · 8 employees · United States · https://autonomix.com